世界の髄膜炎菌ワクチン市場産業概要と2031年までの予測 - 市場分析と市場シェア

世界の髄膜炎菌ワクチン市場 - 業界概要

髄膜炎菌性疾患は、主に脳と脊髄を覆う保護膜である髄膜に影響を及ぼします。全米髄膜炎協会の報告によると、米国では毎年約 600 ～ 1,000 人が髄膜炎菌性疾患に罹患しており、髄膜炎菌性疾患の 21% は 10 代前半、10 代、若年成人が罹患しています。明らかに、これらの統計はワクチンと効果的な治療法の需要を牽引しています。髄膜炎菌性疾患 (髄膜炎や敗血症など) の発生率上昇を防ぐため、ワクチン技術の進歩と包括的なワクチン接種プログラムの導入が積極的に行われています。改良ワクチンの普及とワクチン接種の徹底的な推進が、世界の髄膜炎菌性ワクチン市場の成長を刺激しています。

Data Bridge Market Research の市場レポートでは、最近の新しい開発、市場シェア、セグメンテーションと地域分析に基づく市場動向、市場プレーヤーの影響、新たな収益源の観点から見た機会の分析、市場規制の変更、戦略的な市場成長分析、市場規模、カテゴリ市場の成長、アプリケーションのニッチと優位性、製品の承認、製品の発売、地理的拡大、市場における技術革新などの詳細が提供されます。市場に関する詳細情報を入手するには、Data Bridge Market Research の専門アナリスト チームにお問い合わせください。当社のチームは、情報に基づいた市場決定を行い、ビジネスの成長を達成できるようお手伝いします。

世界の髄膜炎菌ワクチン市場規模

Meningococcal diseases pose severe health risks, with 10-15% of affected individuals succumbing to the illness. Among survivors, approximately 20% endure permanent disabilities, such as brain damage, hearing loss, kidney failure, or limb amputations. These alarming statistics underscore the urgency for comprehensive vaccination programs and advancements in vaccine technology, which are pivotal in mitigating the impact of these life-threatening conditions. Consequently, the demand for effective meningococcal vaccines continues to drive market expansion and innovation. As a result Databridge Market Research dived into comprehensively analyzing the market and unveiled that the Global Meningococcal Vaccines   Market is increasing at a CAGR of 6.70%. Our detailed analysis forecasts that the market is valued at USD 3.49 million in 2023 and is expected to grow up to USD 5.50 million by 2031. Our meticulously created report, developed through comprehensive research and analytics, is a distinguished paper that unveils eye-opening data about the market.

Global Meningococcal Vaccines Market Dynamics

Global Meningococcal Vaccines Market Growth Drivers

Progress in Vaccine Technology

Innovations such as the development of multi-valent vaccines that cover multiple serogroups (A, B, C, W, Y) are expanding protection and driving market growth. For instance, the introduction of the MenB-FHbp vaccine targets serogroup B strains more effectively. Such advancements in vaccine technology not only expand coverage but also drive increased meningococcal vaccines market demand.

Increasing Prevalence of Meningococcal Diseases

According to Centers for Disease Control and Prevention U.S. Cases of meningococcal disease have increased sharply since 2021 and now exceed pre-pandemic levels. In 2023, 422 confirmed and probable cases were reported. This is the largest number of the U.S. meningococcal disease cases reported since 2014. This rise in disease incidence underscores the urgent need for effective vaccination programs, fueling demand for meningococcal vaccines and contributing to Global Meningococcal Vaccines Market Growth.

Global Meningococcal Vaccines Market growth Opportunities

Increasing Research and Development Initiatives

The presence of multiple existing vaccines and ongoing Phase III research activities, with several vaccines expected to be commercialized during the forecast period, is projected to drive market growth. For instance, in June 2020, Pfizer, Inc. began Phase III clinical trials for PF-06886992, a pentavalent meningococcal vaccine candidate (MenABCWY), to assess and compare its safety, immunogenicity, and tolerability with current licensed meningococcal vaccines in adolescents and young adults.

Government Initiatives and Funding

Government support and funding for meningococcal vaccination programs offer significant opportunities for market expansion. Initiatives from organizations such as GAVI and various national health agencies are facilitating vaccine accessibility and affordability. For instance, in Australia, the National Immunization Program provides free meningococcal vaccines to infants and adolescents, ensuring widespread vaccination and reducing disease incidence thereby driving market growth through enhanced public health efforts.

Global Meningococcal Vaccines Market growth Challenges

Limited Access in Low-Income Regions

In many developing countries, healthcare infrastructure and distribution networks are underdeveloped, making it difficult to reach remote or underserved populations. For instance, in regions of sub-Saharan Africa where meningococcal disease is prevalent, logistical challenges and financial constraints can hinder vaccine distribution and uptake.

Vaccine Hesitancy and Low Uptake

Despite the availability of meningococcal vaccines, some communities may harbor concerns or misconceptions about their safety and efficacy, which can hinder vaccination efforts. For instance, in parts of India, misinformation about vaccines has resulted in lower uptake rates, especially in rural areas with limited access to reliable health information. This challenge impacts the global meningococcal vaccines market by reducing vaccination coverage and effectiveness

Global Meningococcal Vaccines Market Restraints

Restraining regulatory Compliances

In Brazil, the Agência Nacional de Vigilância Sanitária (ANVISA) regulates vaccine safety and efficacy, while Australia’s Therapeutic Goods Administration (TGA) sets its own standards for vaccine approval. Adapting to these varied regulatory requirements across different markets can be complex and resource-intensive for vaccine manufacturers, potentially hindering Global Meningococcal Vaccines Market growth.

Global Meningococcal Vaccines Market Scope and Trends

• The bivalent MenACWY vaccine has been updated to enhance its efficacy and broaden coverage, addressing evolving strains against both serogroups A and C and improving protection against meningococcal disease.
• The MenB vaccines, Bexsero and Trumenba, have been incorporated into vaccination schedules for infants, offering protection against serogroup B, which is prevalent in young children.
• The FDA approved the MenQuadfi vaccine, a quadrivalent meningococcal vaccine that provides protection against serogroups A, C, W, and Y, and is now recommended for adults, including those at higher risk such as travelers and military personnel.

Global Meningococcal Vaccines Market Regional Analysis – Market Trends

Key Insights

• North American region is driven by high vaccination coverage and government initiatives. The United States leads with robust immunization programs, supported by CDC guidelines that promote routine vaccination for adolescents and at-risk populations.
• Asia-Pacific’s rapidly growing markets like India and China are witnessing increased adoption due to rising awareness and government efforts to include meningococcal vaccines in national immunization programs. However, challenges like vaccine hesitancy in rural areas persist.
•  Europe's market benefits from strong healthcare infrastructure and government-backed vaccination campaigns, particularly in the UK, where the NHS includes meningococcal vaccines in the national immunization schedule.
• Middle Eastern & African region is experiencing growth due to international health organizations’ efforts, such as GAVI, focusing on expanding vaccine coverage to prevent serotype A outbreaks in the African meningitis belt.

Global Meningococcal Vaccines Market Leading Players

• Johnson & Johnson Private Limited (U.S.)
• Mylan N.V. (U.S.)
• Sun Pharmaceutical Industries Limited (India)
• Sanofi S.A.(France)
• Merck & Co., Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• AbbVie Inc. (U.S.)
• Fresenius Kabi AG (Germany)
• Amneal Pharmaceuticals LLC. (U.S.)
• Pfizer Inc. (U.S.)
• Serum Institute of India Pvt. Ltd (India)
• Incepta Pharmaceuticals Ltd. (India)
• Walvax Biotechnology Co., Ltd (China)
• Bio-Manguinhos (Brazil)

Global Meningococcal Vaccines Market Recent Developments

• In May, 2024 FDA accepts GSK’s pentavalent meningococcal vaccine for review.
• In April, 2024 in a world first, Nigeria has introduced a new 5-in-1 vaccine targeting meningitis, aiming to enhance protection against multiple strains of the disease.
• In June, 2024 Biovac has secured agreements with Sanofi and EuBiologics to strengthen the supply of polio and meningitis vaccines across Africa, enhancing the continent's vaccine availability and healthcare infrastructure.
• 2024年12月、ファイザー社のペンブラヤワクチンは、青少年の髄膜炎菌感染症を引き起こす最も一般的な血清群に対する予防効果を米国FDAから承認されました。

SKU-57165